Eli Lilly to Launch a GLP-1 Pill to Rival Ozempic, but There’s a Catch
The new drug will target weight loss for people with obesity and type 2 diabetes.
Daily oral GLP-1 pill a promising alternative to injectables for weight loss, clinical trial finds
A new oral GLP-1 medication can help adults with obesity and type 2 diabetes lose more weight and improve their blood sugar levels compared to a placebo, according to findings from the ATTAIN-2 trial led by a UTHealth Houston researcher.
JCM, Vol. 14, Pages 8326: Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed
JCM, Vol. 14, Pages 8326: Diabetes Mellitus and Chronic Kidney Disease: The Future Is Being Surpassed Journal of Clinical Medicine doi: 10.3390/jcm14238326 Authors: Alberto Martínez-Castelao José Luis Górriz Beatriz Fernández-Fernández María José Soler Juan F. Navarro-González Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney […]
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1 – Seeking Alpha
Can Novo unravel Lilly rally with Alzheimer’s data for GLP-1 Seeking Alpha High-stakes Novo Nordisk Alzheimer’s studies could yield answers on GLP-1 benefit Reuters Can GLP-1 drugs treat Alzheimer’s? Novo Nordisk will soon announce key results statnews.com Key facts: Novo Nordisk trials Rybelsus for cognitive decline; analysts see stable growth TradingView Novo Nordisk Will Soon Reveal Whether Its GLP-1 […]
Novo Launches Studies to See Whether GLP-1 Drugs Can Slow Alzheimer’s
Post Content
‘Not the MAHA that we signed up for’: Robert F. Kennedy Jr. learns the perils of power and keeping his grassroots movement together
Robert F. Kennedy Jr. spent a recent Wednesday showered in praise from the vice president and health technology CEOs at a glitzy “Make America Healthy Again” event in Washington, designed to celebrate the health secretary’s successes and the movement he has built. Yet online, a different narrative of his tenure was playing out as a small but vocal group […]
GLP-1 Market Incentives, Pharma Partnerships, and AI Restrictions:
A Consolidated Overview Continue reading on Penny Press »
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant?
Over the past several years, GLP-1 agonist weight-loss drugs have evolved from a celebrity trend to arguably the hottest growth opportunity in the pharmaceutical industry. Novo Nordisk (NYSE: NVO) jumped out to an early lead with the immense popularity of its Ozempic and Wegovy (semaglutide), used to treat type 2 diabetes and obesity. However, a […]
Biology, Vol. 14, Pages 1650: GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects
Biology, Vol. 14, Pages 1650: GLP-1 Receptor Signaling and Oral Dysfunction: A Narrative Review on the Mechanistic Basis of Semaglutide-Related Oral Adverse Effects Biology doi: 10.3390/biology14121650 Authors: Milena Barać Jelena Roganović This review addresses the growing concern of oral side effects, particularly dry mouth, associated with semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA) widely used […]
Nutrients, Vol. 17, Pages 3659: Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery?
Nutrients, Vol. 17, Pages 3659: Macronutrient, Micronutrient Supplementation and Monitoring for Patients on GLP-1 Agonists: Can We Learn from Metabolic and Bariatric Surgery? Nutrients doi: 10.3390/nu17233659 Authors: Rhea Sibal G. Balamurugan Jasmine Langley Yitka Graham Kamal Mahawar Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for people living with obesity and type 2 diabetes […]